An Israeli biotech gambles on a failed drug, merging with troubled Menlo ahead of PhIII data
After taking a pair of torpedoes at the waterline last year, a listing Menlo Therapeutics $MNLO is casting its lot with Israeli dermatology biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
